Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. “Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma ...

Beyond Libtayo, Regeneron's oncology pipeline includes several promising programs that could add significant revenue the coming years. Fianlimab is the company’s LAG3 antibody, which has ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve as a foundation for future oncology combination regimens. Eylea has become the leading franchise in ...